dc.contributor.author |
Peloquin, Charles A. |
|
dc.contributor.author |
Phillips, Patrick P. J. |
|
dc.contributor.author |
Mitnick, Carole D. |
|
dc.contributor.author |
Eisenach, Kathleen |
|
dc.contributor.author |
Patientia, Ramonde F. |
|
dc.contributor.author |
Lecca, Leonid |
|
dc.contributor.author |
Gotuzzo Herencia, José Eduardo |
|
dc.contributor.author |
Gandhi, Neel R. |
|
dc.contributor.author |
Butler, Donna |
|
dc.contributor.author |
Diacon, Andreas H. |
|
dc.contributor.author |
Martel, Bruno |
|
dc.contributor.author |
Santillan, Juan |
|
dc.contributor.author |
Hunt, Kathleen Robergeau |
|
dc.contributor.author |
Vargas, Dante |
|
dc.contributor.author |
von Groote-Bidlingmaier, Florian |
|
dc.contributor.author |
Seas Ramos, Carlos Rafael |
|
dc.contributor.author |
Dianis, Nancy |
|
dc.contributor.author |
Moreno-Martinez, Antonio |
|
dc.contributor.author |
Kaur, Pawandeep |
|
dc.contributor.author |
Horsburgh, C. Robert |
|
dc.date.accessioned |
2018-11-30T17:17:13Z |
|
dc.date.available |
2018-11-30T17:17:13Z |
|
dc.date.issued |
2018 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/4096 |
|
dc.description.abstract |
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
American Society for Microbiology |
|
dc.relation.ispartofseries |
Antimicrobial Agents and Chemotherapy |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
tuberculosis |
en_US |
dc.subject |
antitubercular agents |
en_US |
dc.subject |
levofloxacin |
en_US |
dc.subject |
pharmacokinetics |
en_US |
dc.title |
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1128/aac.00770-18 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.03.08 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.05 |
|
dc.relation.issn |
1098-6596 |
|